Ledaga recommended by NICE for rare type of lymphoma
Draft guidance recommends Ledaga for early-stage mycosis fungoides-type cutaneous T-cell lymphoma
Read More
Tag: Ledaga
EU nod for Actelion’s rare immune system cancer drug
Actelion has bagged European Union Approval for Ledaga, its treatment for mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL), a rare potentially life-threatening immune system cancer that appears in the skin.
Read More
December CHMP decisions bring year’s total approvals to 81
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has backed seven new medicines for approval at its December meeting, bringing the total number recommended during the year to 81, dropping from 2015’s tally of 93.
Read More
- Lario Therapeutics awarded $2.4m to advance calcium channel platform
- Mikrobiomik secures approval for gut‑microbiota therapy for C difficile infection
- Exdensur approved in EU for severe asthma and CRSwNP
- Axol Bioscience acquires Newcells Biotech ophthalmology unit
- Nuclera and leadXpro partner to accelerate structure‑based drug design
